Cyplasin-SC Enters Next Phase of Efficacy Animal Testing
The experiments were devised such that other questions could also be answered: What is the highest dose of Cyplasin-SC(TM) to be tolerated when injected only once? What is the highest dose of Cyplasin-SC(TM) to be tolerated when injected repeatedly and what is the best time interval for the injections? What is the best mode of application either under the skin (subcutaneously), or into a vein (intravenously), or into the body cavity (intraperitoneally)? Positive results from these studies were obtained as all mice injected with Cyplasin-SC(TM) at concentrations toxic for the human melanoma cells survived and the results showed Cyplasin-SC(TM) was well tolerated by the organism. The best application form appears to be a subcutaneous application where Cyplasin-SC(TM) is injected under the skin.
Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill melanoma cancer cells while leaving normal non-cancerous cells untouched. Cyplasin is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as a potential anticancer therapeutic product. Patents have been issued to the Company covering the Cyplasin protein.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.